Funding Arrangement - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Apr. 30, 2021	Jul. 31, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 31, 2022	Dec. 31, 2021	Aug. 04, 2021	Jul. 31, 2020
Funding Arrangement [Line Items]
Grant income			$ 690	$ 378	$ 850	$ 378
Cost Reimbursement Sub-Award Agreement
Funding Arrangement [Line Items]
Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria		4 years
Potential funding amount of award to develop vaccine to prevent shingella infections	$ 500
Grant income			700	$ 400	900	$ 400
Cost Reimbursement Sub-Award Agreement | Maximum
Funding Arrangement [Line Items]
Initial funding committed by award		$ 1,600
Total funding committed by award, available upon achievement of development milestones		$ 15,100
Potential funding period of award to develop vaccine to prevent shingella infections	5 years
CARB-X Agreement
Funding Arrangement [Line Items]
Additional funding committed by award									$ 3,200
Potential funding committed by award							$ 13,900
Grant receivable on unreimbursed, eligible costs incurred			$ 700		$ 700			$ 1,200
CARB-X Agreement | Maximum
Funding Arrangement [Line Items]
Initial funding committed by award										$ 2,700
Additional funding committed by award									3,200
Potential funding committed by award									$ 29,700
CARB-X Agreement | Minimum
Funding Arrangement [Line Items]
Initial funding committed by award										$ 1,600